Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

Prostate Cancer is a leading peer-reviewed Open Access journal published by HINDAWI LTD, dedicated to advancing the field of urology and oncology through high-quality research and innovative studies. Established in 2011, this journal serves as a vital platform for disseminating findings related to prostate cancer diagnostics, treatment strategies, and patient care, striving to collaborate and connect researchers from around the globe. With an impact factor reflective of its critical input in the scientific community, the journal showcases compelling manuscripts, reviews, and case reports that are accessible to a wide audience given its open access policy. Located in London, England, Prostate Cancer has made significant strides in its category quartiles, achieving Q4 in Cancer Research and Q3 in both Oncology and Urology as of 2023, reflecting its growing relevance and readership. With Scopus rankings indicating its position within the broader medical fields, the journal is a valuable resource for researchers, professionals, and students alike, contributing to the collective effort to improve outcomes in prostate cancer research and treatment.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Indian Journal of Urology, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to the field of urology, serving as a vital platform for researchers and clinicians to disseminate groundbreaking findings since its inception in 2001. With an ISSN of 0970-1591 and an E-ISSN of 1998-3824, this journal has established itself as a crucial resource for advancing knowledge in urological practices, particularly within the Indian context. Recognized in the 2023 Scopus Rankings with a classification of Q3 in Urology, it stands at a significant position (Rank #71 out of 120) with a 41st percentile performance, highlighting its role in contributing to the global discourse in urological medicine. The journal provides open access options, ensuring that high-quality research is readily available to a broad audience, fostering collaboration and innovation. Publishing significant studies from various converged years, including from 1984 to 1999 and more recently from 2006 to 2024, Indian Journal of Urology is essential for professionals seeking to stay updated with the latest advances and best practices in urology.

Frontiers in Oncology is a premier open access journal dedicated to advancing the field of oncology through innovative research and knowledge dissemination. Published by FRONTIERS MEDIA SA since 2011, this journal is based in Switzerland and holds an impressive Q2 ranking in both Cancer Research and Oncology as of 2023, highlighting its significance in the academic community. With its commitment to open access, Frontiers in Oncology ensures that vital research is readily available to researchers, healthcare professionals, and students around the globe, enhancing collaboration and fostering breakthroughs in cancer research. The journal's robust Scopus rankings further illustrate its academic influence, with notable positions in the fields of Oncology and Cancer Research. By covering a wide range of topics within oncology, this journal serves as a vital resource, supporting the rapid evolution of cancer treatment, diagnostics, and patient care strategies.

Prostate International is a leading open-access journal published by Elsevier Inc, dedicated to advancing research and knowledge in the field of urology, particularly focusing on prostate health and disease. Since its inception in 2013, the journal has preserved its commitment to disseminating high-quality, peer-reviewed articles that contribute significantly to clinical practices and scientific understanding. With an impressive Q1 ranking in urology and a current position as rank #35/120 among urology journals in Scopus, it occupies a prominent place in the academic landscape, ensuring that cutting-edge research reaches a broad audience. The journal's open-access policy enhances visibility and accessibility, fostering collaboration among researchers, healthcare professionals, and students. With the range of topics covered, from innovative treatments to diagnostic advancements, Prostate International serves as a vital resource for those committed to improving patient outcomes and driving the future of urological health.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.